2Miesegaes G, Lute S, Brorson K. Analysis of viral clearance utail operations for monoclonal antibodies [J]. Biotechnol Bioeng, 2010, 106 (2): 238-246.
3Brorson K, Brown J, Hamilton E, et al. Identification of protein A media performanee attributes that c;an be monitored as surrogates for retrovirus clearance during extended re-use [J]. J Chromatogr A, 2003, 989 (1): 155-163.
4Tharakan J, Highsmith F, Clark D, et al. Physical and biochemical characterization of five commercial resins for immunoaffinity purification of factor IX [J]. J Chromatogr, 1992, 595 (1-2): 103- 111.
5Bill E, Lutz U, Karlsson BM, et al. Optimization of protein G chromatography fots biopharmaceutical motloclonal antibodies [J ]. J Mot Recognit, 1995, 8 (1-2) : 90-94.
6Godfrey MA, Kwasowski P, Clift R et ol. Assessment of the suit- ability of commercially available SpA affinity solid phases for the purification of murine monoclonal atttlbodies at process scale [J]. J Immunol Methods, 1993, 160 ( 1 ): 97-105,.
7I Jiang C, Liu J, Rubaeha M, etal. A mechanistic study of Protein A chromatography resin lifetime [J]. J Ghromatogr A, 2009, 1216 (31) : 5849-5855.
8Lute S, Norling L, Hanson M, et al. Robustness of virus removal by protein A chromatography is independent of media lifetime [ J ]. J Chromatogr A, 2008, 1205 (1-~)j 17-25.
